Optimal Treatment Plan for Post-MI Patient with Ischemia and Reduced LVEF

Critical Medication Addition Required

• The American College of Cardiology recommends immediate addition of a beta-blocker to the patient's regimen for life-saving intervention in patients with LVEF <50% and evidence of prior myocardial infarction 1
• Beta-blocker therapy is essential to reduce risk of death, recurrent MI, and heart failure hospitalization in patients with reduced LVEF 1

Specific Beta-Blocker Recommendations

• Initiate carvedilol, metoprolol succinate, or bisoprolol as these agents have proven mortality benefit in patients with reduced LVEF 1
• Start at low doses and titrate upward to target doses over several weeks 1
• Reassess symptoms, blood pressure, heart rate, renal function, and potassium levels 1-2 weeks after initiating beta-blocker and after any dose adjustments 1

Statin Intensification Required

• Increase atorvastatin from 40 mg to 80 mg daily immediately to target LDL-C <70 mg/dL or at least 50% reduction from baseline 1
• High-intensity statin therapy should be started as early as possible and maintained long-term in all post-MI patients 1

Consider Adding Mineralocorticoid Receptor Antagonist

• Add spironolactone or eplerenone if the patient has heart failure symptoms or diabetes, provided renal function is adequate and potassium is normal 1
• This is recommended for patients with ejection fraction <40% who are already receiving an ACE inhibitor/ARB and beta-blocker 1

Gastrointestinal Protection

• Add a proton pump inhibitor given the patient is on dual antiplatelet therapy with Brilinta and has high risk for gastrointestinal bleeding 1

Current Medications - Continue with Modifications

• Continue Brilinta 60 mg twice daily for 12 months post-PCI unless excessive bleeding risk develops, as recommended by the European Society of Cardiology 2, 1
• Ticagrelor is appropriate for patients at moderate to high risk of ischemic events with elevated cardiac troponins, according to the European Heart Journal 2

Mandatory Non-Pharmacologic Interventions

• Enroll the patient in a cardiac rehabilitation program immediately, as recommended by the American Heart Association 1
• Provide smoking cessation counseling with repeated advice, follow-up support, and pharmacotherapy if the patient smokes 1
• Implement dietary modifications and regular exercise as part of comprehensive cardiovascular risk reduction, as recommended by the American College of Cardiology 3

Follow-Up and Monitoring Strategy

• Repeat echocardiography in 3-6 months to assess response to optimized medical therapy and ventricular remodeling, as recommended by the American Society of Echocardiography 1
• Evaluate for implantable cardioverter-defibrillator for primary prevention of sudden cardiac death if LVEF remains <35% after 3 months of optimal medical therapy 1

Consideration for Invasive Strategy

• Consider an invasive strategy within 72 hours if the patient meets criteria for recent acute coronary syndrome, as recommended by the European Heart Journal 2
• The patient has intermediate-risk criteria, including diabetes, renal insufficiency, LVEF <50%, or known ischemia on non-invasive testing 2